Why Farbe Firma is the Top Manufacturer of Diclofenac Sodium Injection
- Maulik Sudani
- 17 hours ago
- 7 min read
Last Updated: May 28, 2026
TL;DR: Diclofenac Sodium Injection — a sterile parenteral solution of the phenylacetic-acid non-steroidal anti-inflammatory drug (NSAID) diclofenac sodium, supplied most commonly as 25 mg/mL in 1 mL, 2 mL and 3 mL ampoules (25 mg, 50 mg and 75 mg strengths) — is the global workhorse for short-term management of moderate to severe post-operative pain, renal and biliary colic, acute musculoskeletal inflammation, migraine and gout flares where rapid analgesia is needed and an oral route is not feasible. Within 15–30 minutes of intramuscular administration it produces clinically meaningful analgesia by reversibly inhibiting cyclooxygenase-1 and cyclooxygenase-2, suppressing prostaglandin synthesis at the site of injury. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Diclofenac Sodium Injection at our Gujarat, India facility and supplies it to hospital tenders, post-operative pain programmes, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Phenylacetic-acid non-steroidal anti-inflammatory drug (NSAID) — Diclofenac Sodium Injection is one of the most widely used parenteral NSAIDs in the world for short-term post-operative pain, renal and biliary colic, acute musculoskeletal injury, acute migraine and acute gouty arthritis. As a non-narcotic analgesic it allows hospitals to reduce opioid burden without compromising pain control.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, qualified amber-glass ampoule filling lines, dedicated handling for a poorly soluble, pH-sensitive NSAID solubilised in a propylene-glycol-based vehicle, validated terminal-sterilisation cycles and full container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, ICH Q1B photostability data, drug master files and CEP-style documentation for registrations across regulated and emerging markets — including ministry-of-health hospital and post-operative-pain tenders.
End-to-end CDMO services: Contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tender-ready ampoule packaging and logistics coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Diclofenac Sodium Injection Demands a Premium Manufacturer
Diclofenac Sodium Injection occupies a unique position in hospital pharmacy. It is the parenteral NSAID that emergency physicians reach for when a patient walks into the department with renal colic, biliary colic, acute mechanical low-back pain or a migraine that has broken through every oral analgesic; it is the post-operative analgesic that surgical teams use to lower opioid requirements after orthopaedic, gynaecological and general-surgical procedures; and it is the standard intervention in acute gouty arthritis and acute musculoskeletal trauma. Across all of these uses the value proposition is the same — fast, non-narcotic, potent analgesia delivered in a small-volume ampoule that can be given intramuscularly or as a short intravenous infusion. The drug is given to patients who are already in pain, who often have co-morbidities, and who expect relief within thirty minutes.
That clinical reality places real demands on the manufacturer. Diclofenac sodium itself is a poorly water-soluble weak acid that must be solubilised for parenteral use in a co-solvent system — typically a mixture of propylene glycol, benzyl alcohol and a buffer — at a tightly controlled pH (around 7.8 to 8.9). The resulting solution is photosensitive and is normally packed in amber glass ampoules with light-protective secondary cartons. Assay must be controlled across a narrow window because under- or over-dosing a 75 mg dose has direct consequences for analgesia and for renal and gastrointestinal safety. The drug is also injected into muscle, where excipient irritation, particulates and pH excursions translate directly into injection-site pain. Choosing a Diclofenac Sodium Injection manufacturer that treats solubilisation, pH control, photostability and particulate inspection as core engineering disciplines is what protects emergency and post-operative analgesia at the bedside.
What Sets a World-Class Diclofenac Sodium Injection Manufacturer Apart
A world-class manufacturer of Diclofenac Sodium Injection invests in three areas that weaker suppliers underfund: a robust co-solvent formulation that holds diclofenac in stable solution without precipitation, photostability and oxidative-stability control across the shelf life, and tender-ready dossier support for a product that almost always moves through hospital and ministry-of-health procurement. It starts with the active pharmaceutical ingredient — pharmacopoeial-grade diclofenac sodium sourced from qualified, audited API manufacturers, with full impurity profiling, related-substances control and certificates of analysis cross-checked by the receiving laboratory before any material enters production.
Formulation, filling and packaging then have to protect the molecule end to end. The solution is built at a controlled alkaline pH with propylene glycol, benzyl alcohol and a sodium-metabisulphite or equivalent antioxidant where needed, and is filled under ISO Class 5 air into amber-glass ampoules with light-protective secondary cartons. In-process assay confirms label strength, container-closure integrity is verified on every batch, and stability is tracked under ICH Q1A long-term and accelerated conditions as well as ICH Q1B photostability protocols. Critically, the artwork programme keeps the 25 mg, 50 mg and 75 mg strengths visually distinct — different ampoule colours, different carton colours, large strength callouts — because these strengths are routinely stocked together in emergency departments and post-operative wards where selection errors must not occur.
Quality Systems Behind Every Diclofenac Sodium Injection
Every Farbe Firma Diclofenac Sodium Injection batch is released only after a full stack of quality checks: HPLC assay against USP, BP, IP or EP reference standards, related-substances and degradation-product profiling, pH, osmolarity, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, container-closure integrity, and fill-volume verification for the 1 mL, 2 mL and 3 mL ampoule formats. Certificates of analysis are issued with full traceability back to API lot, primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, calibrated sterilisation and depyrogenation equipment, validated terminal sterilisation cycles with load mapping for each container format, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Stability is tracked under both long-term (30 °C / 65 % RH) and accelerated (40 °C / 75 % RH) ICH Q1A conditions — Zone IVb included — and the product is challenged against ICH Q1B photostability requirements so we can assure customers that the Diclofenac Sodium Injection they buy today will still meet specification when it reaches the emergency department or post-operative ward months later in any climate.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Diclofenac Sodium Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables across pain-management, anaesthesia, anti-infective, obstetric, neonatal and supportive-care categories. For Diclofenac Sodium Injection specifically, we supply 25 mg, 50 mg and 75 mg strengths in 1 mL, 2 mL and 3 mL amber-glass ampoules under WHO-GMP conditions, with country-specific strengths, container formats and pack configurations available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier ready to hand for registration in the buyer's target market.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics to the destination. When a buyer needs Diclofenac Sodium Injection at tender scale — and emergency, post-operative and ministry-of-health pain procurements are almost always high-volume, multi-strength and label-sensitive — our regulatory, manufacturing and logistics teams move as one: dossier, artwork, production slot and shipment plan delivered as a single coordinated package, with a single accountable point of contact.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor; our quality unit answers technical queries with primary data, not slogans; and our reviewer team — practising pharmacists and R&D scientists — can talk through API sourcing, co-solvent formulation, pH control, photostability, sterilisation, container-closure and stability choices in real detail. For a drug given to patients already in pain, in emergency rooms and on surgical wards, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Diclofenac Sodium Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Diclofenac Sodium Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, qualified amber-glass ampoule filling lines, qualified water-for-injection systems, validated terminal sterilisation cycles and continuous environmental monitoring. WHO-GMP, USP, BP, IP and EP compliance documentation is available on request.
Which strengths and pack sizes of Diclofenac Sodium Injection do you supply?
Our standard presentations are 25 mg/mL diclofenac sodium solution in 1 mL, 2 mL and 3 mL amber-glass ampoules (25 mg, 50 mg and 75 mg per ampoule). Custom fill volumes, vial presentations and country-specific pack configurations are available under contract manufacturing agreements — share your specification and our technical team will quote within 48 hours.
Can Farbe Firma support country-specific registrations for Diclofenac Sodium Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. Our regulatory team has supported registrations across 30+ countries in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
How does Farbe Firma assure the potency and stability of Diclofenac Sodium Injection?
We control pH within a validated alkaline specification, run HPLC assay and related-substances testing on every batch, package in amber-glass ampoules with light-protective secondary cartons, and qualify each batch against ICH Q1A long-term and accelerated stability protocols plus ICH Q1B photostability. Endotoxin, sterility and container-closure integrity are confirmed on every batch.
What is the minimum order quantity for Diclofenac Sodium Injection contract manufacturing?
MOQs vary by strength, container format, label complexity and dossier requirements. For the 25 mg, 50 mg and 75 mg ampoule presentations we accommodate hospital-scale and full-tender-scale orders. Contact director@farbefirma.org for a specific quotation against your specification.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments